GHRP-6

GHRP-6 10MG

Manufacturer: Novo
Package: 10 mg/vial
Common Names: GHRP-6, Growth Hormone-Releasing Peptide-6, Hexarelin-related Growth Hormone Secretagogue

Info: GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It has been investigated for its ability to stimulate endogenous growth hormone release through activity at the ghrelin receptor. GHRP-6 has attracted research interest because of its effects on growth hormone secretion, appetite regulation, and endocrine signaling.

Growth Hormone Research: GHRP-6 has been studied for its ability to stimulate the release of growth hormone from the pituitary gland. Experimental research indicates that its effects may vary according to dose, administration route, baseline endocrine status, and individual physiological factors.

Appetite and Metabolic Research: GHRP-6 has also been investigated for its effects on appetite and feeding behavior. These effects are associated with its interaction with ghrelin-related signaling pathways and may occur alongside changes in growth hormone secretion.

Dosage Range and Duration of Use

In research and clinical protocols, subcutaneous administration typically ranges from 100 mcg to 300 mcg per dose, taken two to three times daily on an empty stomach (typically 30–60 minutes before meals or before bed). Standard experimental cycles generally last between 8 to 12 weeks, followed by a break to prevent receptor desensitization. GHRP-6 should be used only under appropriate medical supervision and according to applicable regulatory requirements.    

Side Effects

Because GHRP-6 has not been established as an approved therapeutic treatment for routine clinical use, its complete long-term safety profile in humans has not been determined. Potential or reported reactions may include increased appetite, headache, dizziness, fatigue, nausea, injection-site reactions, and alterations in glucose metabolism. Effects may vary depending on exposure, administration route, individual characteristics, and concurrent substances.

Post-Cycle Therapy

GHRP-6 is a growth hormone secretagogue rather than an anabolic steroid, androgenic compound, or testosterone-suppressing anabolic agent. It therefore does not require conventional post-cycle therapy (PCT) protocols associated with anabolic steroid use. However, because GHRP-6 influences growth hormone secretion and endocrine signaling, its use and discontinuation should be considered within an appropriate medical or research framework.

Storage:

Store lyophilized GHRP-6 according to the manufacturer's storage specifications and protect the vial from excessive heat, moisture, and direct exposure to light. After reconstitution, storage requirements and stability may depend on the diluent, concentration, preparation method, and manufacturer's instructions.